Table 2.
Clinical Trials Evaluating Antiangiogenic Agents in Squamous NSCLC
| Study description | Primary endpoint(s) | Target accrual, n | Current statusa |
|---|---|---|---|
| Axitinib + first-line gemcitabine/cisplatin (NCT00735904; phase II) | RR | 38 | Completed |
| Nintedanib + first-line gemcitabine/cisplatin (LUME-Lung 3, NCT01346540; phase I/II) | Phase I: frequency, intensity, and duration of AEs and DLTs Phase II: PFS |
165 | Recruiting |
| Nintedanib or placebo + second-line docetaxel (LUME-Lung 1, NCT00805194; phase III) | PFS | 1,300 | Active, no longer recruiting |
| Cediranib or placebo + first-line carboplatin/paclitaxel (CAN-NCIC-BR29, NCT00795340; phase III) | OS | 306 | Active, no longer recruiting |
| Pazopanib (NCT01208064; phase II/III) | OS | 600 | Recruiting |
| Pazopanib + erlotinib or placebo + erlotinib (NCT01027598; phase II) | PFS | 201 | Active, no longer recruiting |
| Ramucirumab + pemetrexed and carboplatin/cisplatin or + gemcitabine and carboplatin/cisplatin (NCT01160744; phase II) | PFS | 280 | Recruiting |
NSCLC, non-small cell lung cancer; RR, response rate; AEs, adverse events; DLTs, dose-limiting toxicities; PFS, progression-free survival; OS, overall survival.
a
Per ClinicalTrials.gov, accessed November 2013.